Domov › Burkittov limfom › Oregon
Klinične študije za Burkittov limfom v Oregon
8 študij za Burkittov limfom išče udeležence na lokacijah v Oregon.
Mesta v Oregon
Uradno besedilo študije (angleško)
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
- Saint Alphonsus Cancer Care Center-Ontario, Ontario
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- in še 1
Vključevanje udeležencevFaza 3
Starost 18–39 · Vsi spoli · Posodobljeno 2. okt. 2026 · NCT03150693Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
Vključevanje udeležencevFaza 2
Starost 18 in več · Vsi spoli · Posodobljeno 29. sep. 2026 · NCT03739814Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- Oregon Health and Science University ( Site 1004), Portland
Vključevanje udeležencevFaza 1/2
6 Months – 25 Years · Vsi spoli · Posodobljeno 17. sep. 2026 · NCT06395103A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- Legacy Emanuel Children's Hospital, Portland
- Oregon Health and Science University, Portland
Vključevanje udeležencevFaza 2
Starost 1–30 · Vsi spoli · Posodobljeno 1. sep. 2026 · NCT04546399Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- Legacy Emanuel Children's Hospital, Portland
- Oregon Health and Science University, Portland
Vključevanje udeležencevFaza 3
365 Days – 25 Years · Vsi spoli · Posodobljeno 25. avg. 2026 · NCT03959085Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
- Oregon Health & Science University, Portland
Vključevanje udeležencevFaza 2
Starost 7–25 · Vsi spoli · Posodobljeno 19. avg. 2026 · NCT05082519Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- Oregon Health & Science University, Portland
Vključevanje udeležencevFaza 1/2
Starost 13–90 · Vsi spoli · Posodobljeno 6. avg. 2026 · NCT06533579Study of SGR-1505 in Mature B-Cell Neoplasms
- Oregon Health and Science University - Knight Cancer Institute, Portland
Vključevanje udeležencevFaza 1
Starost 18 in več · Vsi spoli · Posodobljeno 13. feb. 2026 · NCT05544019Vir: ClinicalTrials.gov, podatki pridobljeni 5. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.